FEATURED
Emergex to Launch Phase I Trial for New T-Cell Priming COVID-19 Vaccine
A next-generation COVID-19 vaccine, developed by British biotech Emergex, designed to prime T-Cells to rapidly remove viral-infected cells and offer
DEALS
Japan to Buy 1.6 Mill Courses of Merck’s Oral COVID-19 Antiviral Molnupiravir
Merck (MRK) and Ridgeback Biotherapeutics have announced that the Japanese government will acquire approximately 1.6 million courses of molnupiravir (MK-4482,
PRESS RELEASES
Metformin Processing Station with Potential to Become a Bestseller
L.B. Bohle’s new metformin processing station allows for efficient and high-volume metformin production. Metformin is an oral drug effective for
Comments & Analysis
Machine Learning Tissue Classifiers Power AI in Clinical Research
Machine learning tissue classifiers are one of the most powerful and promising AI-based clinical research solutions for all types of
RESOURCES
Download the latest pharmaceutical case studies, white papers, research papers and product brochures
EScalate Assay Enables Robust and Accurate Determination of Plasma Protein Binding
Determination of the Plasma Protein Binding of Liraglutide Using the EScalate* Equilibrium Shift Assay A Sovicell White Paper Evaluation of
LATEST PROJECTS
Rosalind Franklin Institute, Novel Biological Imaging Technologies, UK
The Rosalind Franklin Institute, a new research institute dedicated to developing novel technologies to tackle important health research challenges has
CLINICAL TRIALS
Emergex to Launch Phase I Trial for New T-Cell Priming COVID-19 Vaccine
A next-generation COVID-19 vaccine, developed by British biotech Emergex, designed to prime T-Cells to rapidly remove viral-infected cells and offer
REGULATORY
First Oral COVID-19 Antiviral Medicine Approved in the UK
Merck and Ridgeback’s Molnupiravir has become the world’s first approved oral COVID-19 antiviral drug. Molnupiravir has been authorised by the
